Historical Valuation
Protalix Biotherapeutics Inc (PLX) is now in the Undervalued zone, suggesting that its current forward PS ratio of 1.86 is considered Undervalued compared with the five-year average of 5.17. The fair price of Protalix Biotherapeutics Inc (PLX) is between 1976.17 to 1978.15 according to relative valuation methord. Compared to the current price of 2.07 USD , Protalix Biotherapeutics Inc is Undervalued By 99.9%.
Relative Value
Fair Zone
1976.17-1978.15
Current Price：2.07
99.9%
Undervalued
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
Protalix Biotherapeutics Inc (PLX) has a current Price-to-Book (P/B) ratio of 2.64. Compared to its 3-year average P/B ratio of 14.43 , the current P/B ratio is approximately -81.68% higher. Relative to its 5-year average P/B ratio of 20.16, the current P/B ratio is about -86.89% higher. Protalix Biotherapeutics Inc (PLX) has a Forward Free Cash Flow (FCF) yield of approximately -8.36%. Compared to its 3-year average FCF yield of -5.34%, the current FCF yield is approximately 56.51% lower. Relative to its 5-year average FCF yield of -14.66% , the current FCF yield is about -43.00% lower.
P/B
Median3y
14.43
Median5y
20.16
FCF Yield
Median3y
-5.34
Median5y
-14.66
Competitors Valuation Multiple
AI Analysis for PLX
The average P/S ratio for PLX competitors is 7730.84, providing a benchmark for relative valuation. Protalix Biotherapeutics Inc Corp (PLX.A) exhibits a P/S ratio of 1.86, which is -99.98% above the industry average. Given its robust revenue growth of -0.60%, this premium appears unsustainable.
Performance Decomposition
AI Analysis for PLX
1Y
3Y
5Y
Market capitalization of PLX increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.
The secondary factor is the Unknown, contributed 0.00%to the performance.
Overall, the performance of PLX in the past 1 year is driven by Unknown.
People Also Watch
Frequently Asked Questions
Is PLX currently overvalued or undervalued?
Protalix Biotherapeutics Inc (PLX) is now in the Undervalued zone, suggesting that its current forward PS ratio of 1.86 is considered Undervalued compared with the five-year average of 5.17. The fair price of Protalix Biotherapeutics Inc (PLX) is between 1976.17 to 1978.15 according to relative valuation methord. Compared to the current price of 2.07 USD , Protalix Biotherapeutics Inc is Undervalued By 99.90% .
What is Protalix Biotherapeutics Inc (PLX) fair value?
PLX's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Protalix Biotherapeutics Inc (PLX) is between 1976.17 to 1978.15 according to relative valuation methord.
How does PLX's valuation metrics compare to the industry average?
The average P/S ratio for PLX's competitors is 7730.84, providing a benchmark for relative valuation. Protalix Biotherapeutics Inc Corp (PLX) exhibits a P/S ratio of 1.86, which is -99.98% above the industry average. Given its robust revenue growth of -0.60%, this premium appears unsustainable.
What is the current P/B ratio for Protalix Biotherapeutics Inc (PLX) as of Jan 11 2026?
As of Jan 11 2026, Protalix Biotherapeutics Inc (PLX) has a P/B ratio of 2.64. This indicates that the market values PLX at 2.64 times its book value.
What is the current FCF Yield for Protalix Biotherapeutics Inc (PLX) as of Jan 11 2026?
As of Jan 11 2026, Protalix Biotherapeutics Inc (PLX) has a FCF Yield of -8.36%. This means that for every dollar of Protalix Biotherapeutics Inc’s market capitalization, the company generates -8.36 cents in free cash flow.
What is the current Forward P/E ratio for Protalix Biotherapeutics Inc (PLX) as of Jan 11 2026?
As of Jan 11 2026, Protalix Biotherapeutics Inc (PLX) has a Forward P/E ratio of 9.94. This means the market is willing to pay $9.94 for every dollar of Protalix Biotherapeutics Inc’s expected earnings over the next 12 months.
What is the current Forward P/S ratio for Protalix Biotherapeutics Inc (PLX) as of Jan 11 2026?
As of Jan 11 2026, Protalix Biotherapeutics Inc (PLX) has a Forward P/S ratio of 1.86. This means the market is valuing PLX at $1.86 for every dollar of expected revenue over the next 12 months.